Cover Image

Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant

Idiopathic pulmonary fibrosis (IPF) is a rare and progressive interstitial lung disease characterized by irreversible distortion of lung architecture and subsequent loss of pulmonary function. Pirfenidone is an antifibrotic agent associated with increased progression-free survival and overall surviv...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nicolò Reccardini (Author), Maria Chernovsky (Author), Francesco Salton (Author), Paola Confalonieri (Author), Lucrezia Mondini (Author), Mariangela Barbieri (Author), Antonio Romallo (Author), Marta Maggisano (Author), Chiara Torregiani (Author), Pietro Geri (Author), Michael Hughes (Author), Corrado Campochiaro (Author), Marco Confalonieri (Author), Angelo Scarda (Author), Umberto Zuccon (Author), Barbara Ruaro (Author)
Format:	Book
Published:	MDPI AG, 2024-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows
by: Maria Chianese, et al.
Published: (2024)

Safety of Nintedanib in a Patient with Chronic Pulmonary Fibrosis and Kidney Disease
by: Marta Maggisano, et al.
Published: (2024)

Functional Progression after Dose Suspension or Discontinuation of Nintedanib in Idiopathic Pulmonary Fibrosis: A Real-Life Multicentre Study
by: Barbara Ruaro, et al.
Published: (2024)

Gastrointestinal Manifestations of Sarcoidosis: A State-of-the-Art, Comprehensive Review of the Literature-Practical Clinical Insights and Many Unmet Needs on Diagnosis and Treatment
by: Salvatore Nicolosi, et al.
Published: (2024)

Theory and Practice of Glucocorticoids in COVID-19: Getting to the Heart of the Matter-A Critical Review and Viewpoints
by: Francesco Salton, et al.
Published: (2023)

The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients
by: Barbara Ruaro, et al.
Published: (2021)

Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy
by: Barbara Ruaro, et al.
Published: (2023)

Gastroesophageal Reflux Disease in Idiopathic Pulmonary Fibrosis: Viewer or Actor? To Treat or Not to Treat?
by: Barbara Ruaro, et al.
Published: (2022)

Editorial: Pulmonary fibrosis: One manifestation, various diseases
by: Barbara Ruaro, et al.
Published: (2022)

The Treatment of Lung Involvement in Systemic Sclerosis
by: Barbara Ruaro, et al.
Published: (2021)

IN VITRO EVALUATION OF ANTITHROMBOTIC AND ANTICOAGULANT ACTIVITY OF HERBAL SOURCES
by: G.M. ABDULLINA, et al.
Published: (2024)

Special Issue "Rheumatic Diseases: Pathophysiology, Targeted Therapy, Focus on Vascular and Pulmonary Manifestations 2022"
by: Barbara Ruaro, et al.
Published: (2023)

Biphasic Effect of Pirfenidone on Angiogenesis
by: Donghao Gan, et al.
Published: (2022)

The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
by: Taki Galanis, MD, et al.
Published: (2014)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011)

Ameliorative effects of pirfenidone in chronic kidney disease
by: Samad Ghodrati, et al.
Published: (2022)

O Sistema Único de Saúde e as populações indígenas: por uma integração diferenciada
by: Ulisses E. C. Confalonieri
Published: (1989)

Antithrombotic Regimens in Patients With Percutaneous Coronary Intervention Whom an Anticoagulant Is Indicated: A Systematic Review and Network Meta-Analysis
by: Wipharak Bunmark, et al.
Published: (2018)

Current Antithrombotic Therapy Strategies in Children with a Focus on Off-Label Direct Oral Anticoagulants-A Narrative Review
by: Stefana Maria Moisa, et al.
Published: (2022)

Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
by: KM Roach, et al.
Published: (2021)

Pirfenidone-induced dose-dependent phototoxicity - a distinct drug reaction
by: P Arunprasath, et al.
Published: (2020)

Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
by: Donghao Gan, et al.
Published: (2021)

Pirfenidone-loaded liposomes for lung targeting: preparation and in vitro/in vivo evaluation
by: Meng H, et al.
Published: (2015)

Editorial: Evolution in respiratory pharmacology
by: Barbara Ruaro, et al.
Published: (2023)

ANTITHROMBOTIC THERAPY IN CANCER PATIENTS
by: A. V. Vorobev, et al.
Published: (2016)

Subdural Hemorrhage and Antithrombotic Therapy
by: J Gordon Millichap, et al.
Published: (2014)

Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis
by: Sakayori M, et al.
Published: (2019)

Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
by: Jin-Young Huh, et al.
Published: (2023)

Preparation of novel pirfenidone microspheres for lung-targeted delivery: in vitro and in vivo study
by: Li DB, et al.
Published: (2016)

Efficacy and safety of antithrombotic therapy with non-vitamin K antagonist oral anticoagulants after transcatheter aortic valve replacement: a systematic review and meta-analysis
by: Qing An, et al.
Published: (2021)

Antithrombotic therapy in COVID-19 patients
by: E. V. Slukhanchuk, et al.
Published: (2023)

The Antithrombotic Effect of Recombinant Neorudin on Thrombi
by: Liu YB, et al.
Published: (2022)

Antithrombotic potential of Berberis calliobotrys extract
by: . Alamgeer, et al.
Published: (2016)

ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS
by: V. A. Sulimov
Published: (2016)

ANTITHROMBOTIC ACTIVITY OF SBT-828 COMPOUND
by: V. S. Sirotenko, et al.
Published: (2015)

City puzzles: Does urban land scape affect genetic population structure in Aedes aegypti?
by: Lucía Maffey, et al.
Published: (2022)

In vivo pharmacokinetic and pharmacodynamic study of co-spray-dried inhalable pirfenidone microparticles in rats
by: Ji-Hyun Kang, et al.
Published: (2022)

Preparation of Novel Pirfenidone Microspheres for Lung-Targeted Delivery: In vitro and in vivo Study [Retraction]
by: Li D, et al.
Published: (2022)

Effectiveness of Pharmacist-Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
by: Yukari Satsuma, et al.
Published: (2020)